GlassScriptPhysician profile
Amy Markert Morris
NPI 1912985243
$6,318.51
in general payments reported to CMS, 2019-2025
30 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $48.38 · 2021: $290 · 2022: $526 · 2023: $1,642 · 2024: $1,868 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,676 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,675.74 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.40 | 2019-2025 | |
| Janssen Biotech, INC. | $1,152.04 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $514.83 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $416.00 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Amgen INC. | $344.30 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $340.96 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $289.90 | 2019-2025 | |
| Sensus Healthcare, INC. | $230.55 | 2024 | |
| Dermavant Sciences, INC. | $222.21 | 2023-2024 | Vtama |
| Ucb, INC. | $221.50 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $211.20 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $168.69 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $133.49 | 2021-2025 | Adbry, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $132.49 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $129.54 | 2019-2025 | Nemluvio, Aklief |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $106.98 | 2022-2024 | Libtayo |
| Almirall LLC | $91.41 | 2019-2025 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.95 | 2023-2025 | Spevigo |
| Hill Dermaceuticals, INC. | $85.37 | 2023-2024 | Tolak |
| Celgene Corporation | $40.80 | 2019 | |
| Biofrontera INC. | $39.46 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Medimetriks Pharmaceuticals, INC. | $34.55 | 2019 | |
| Fresenius Kabi USA, LLC | $30.39 | 2023 | Idacio |
| Botanix Sb INC | $30.02 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $22.14 | 2025 | Spinosad, Natroba |
| Mallinckrodt Hospital Products INC. | $21.32 | 2025 | Acthar |
| Prugen, INC. Pharmaceuticals | $20.42 | 2019 | |
| Genzyme Corporation | $17.55 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.81 | 2022 | |
| Strata Skin Sciences, INC. | $13.24 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.